Pirche is a global technology leader in the application of AI to molecular medicine. Its back end epitope matching technology is redefining compatibility risk assessment as a prerequisite for foreign tissue or allogeneic cells to be accepted by the patient immune system. Pirche‘s front end product is a first and only-in-class proprietary digital diagnostic platform that enables physicians and drug developers to make informed decisions with unprecedented precision. Over 850 leading clinics worldwide are networked with Pirche. Based on its fundamental IP, Pirche is partnering with industry leaders to make a profound impact on the future of healthcare in transplant medicine, autoimmunity and oncology.

Field of Activity	In transplant medicine, donor-recipient risk assessment to improve organ survival and management of long-term immunosuppression, and in allogeneic cell therapy, design and ‘off-the-shelf’ selection utilizing immune risk profi ling in autoimmunity and oncology
Ownership structure and financing	German Stock corporation (Aktiengesellschaft); A-series upcoming; break-even within 24 months expected
Partners	Thermo Fisher Scientific, Immucor; 850+ clinics and transplant centers globally
Technology	The epitope matching technology combines genetic typing with realtime AI-supported immunological simulations of protein interactions. Protected by 25 gratec patents and a proven medical evidence with 70+ peer reviewed publications on more than 200,000 patient cases.
Products/services	Fully digital diagnostic platform and prediction pipeline based on standard lab data for donor-recipient risk assessment, management of immunosuppression and support of allogeneic cell therapy design and allocation.
Unique selling point	Pirche‘s patented epitope matching technology transforms transplant medicine and cell therapies driven by exclusive AI algorithms, solid science, and forward-thinking industry partners.
Membership in networks/associations	ASHI – American Society for Histocompatibility and Immunogenetic; TTC – Transplant Therapeutics Consortium; Bio Deutschland
Date of Incorporation/Number of Employees	08/2015/15 employees
contact:
Adresse	US: 266 Main Street, Medfield, MA 02052 EU: Nördliche Münchner Straße 27a, 82031 Grünwald, Germany
Telefon	Medfield: +1 617 233 7699 Grünwald: +49 89 9090 153 914
E-Mail	Thomas Klein is your contact for spoken communication: thomas.klein@pirche.com
Web-Adresse	https://pirche.com
Social Media	LinkedIn